CRISPR-SCD-001

N/A

Report date: 2025/01/26 18:08:00

Base Information

Drug NameCRISPR-SCD-001

Drug Alias NameCRISPR gene correction therapy (Univeristy of California Los Angeles)CD34-positive hematopoietic stem cell-based gene therapy (Univeristy of California Los Angeles)CRISPR-SCD-001

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapy

Mechanisms of ActionHemoglobin beta chain stimulants

TargetsHemoglobin beta chain

Therapy Area/IndicationsAnemia, Sickle Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesUniversity Of California, Los Angeles

China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California, Los Angeles

Inactive CompaniesN/A

Active IndicationsAnemia, Sickle Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A